332 related articles for article (PubMed ID: 22175139)
1. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
Amano K
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
[No Abstract] [Full Text] [Related]
2. [Biological therapies in rheumatology].
Von Frenckell C; Malaise MG
Rev Med Liege; 2009; 64(5-6):293-300. PubMed ID: 19642462
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
[TBL] [Abstract][Full Text] [Related]
4. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF therapy.
Thalayasingam N; Isaacs JD
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):549-67. PubMed ID: 22137924
[TBL] [Abstract][Full Text] [Related]
6. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
8. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
Gabay C; Hasler P; Kyburz D; So A; Villiger P; von Kempis J; Walker U
Swiss Med Wkly; 2014; 144():w13950. PubMed ID: 24723273
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel FA; Strober BE
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
[TBL] [Abstract][Full Text] [Related]
10. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials.
Liu Y; Fan W; Chen H; Yu MX
Asian Pac J Cancer Prev; 2014; 15(8):3403-10. PubMed ID: 24870729
[TBL] [Abstract][Full Text] [Related]
11. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
12. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
Neovius M; Askling J
Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
[No Abstract] [Full Text] [Related]
13. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
[TBL] [Abstract][Full Text] [Related]
14. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
15. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
16. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
Sibilia J
Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
[TBL] [Abstract][Full Text] [Related]
17. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
18. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
19. Which TNF inhibitor for rheumatoid arthritis?
Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
[No Abstract] [Full Text] [Related]
20. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
Jansen JP; Buckley F; Dejonckheere F; Ogale S
Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
